All immediate challenges to the status of abortifacient mifepristone on the US market are on ice for the near future after the Supreme Court on Apr. 21 — without considering the merits of the case — approved a Justice Department request to put temporarily suspend recent rulings by a federal district court and an appeals court.
All changes to the US use of abortifacient mifepristone are now on hold – for three more days – pending a review by Supreme Court Justice Samuel Alito of two complex and differing lower court decision on lawsuits brought by anti-abortion groups.
After failing yet again this week to overturn a judgment rejecting its plans to roll into a separate company more than 38,000 lawsuits claiming that its talc-based baby powder causes cancer, US healthcare giant Johnson & Johnson said it intends to file for a stay of the opinion and take its case to the Supreme Court.
As abortion continues to dominate the political discussion in the US and at least half of the 50 states move toward outlawing the procedure in response to last summer’s Supreme Court decision that it is not a constitutional right, conservative and religious groupings are pushing for a ban on sales of the oral abortifacient Mifeprex. (mifepristone).
In the wake of the US Supreme Court’s recent overturn of Roe v. Wade, a 50-year-old decision by an earlier team of justices that guarantees women the right terminate a pregnancy, attention has turned to the so-called morning-after pill mifepristone – which remains legal for now – and easier access to birth control.
The administration of US president Joe Biden is looking for ways to work around the Supreme Court’s recent landmark ruling that limits the Environmental Protection Agency’s role in regulating emissions of greenhouse gases.
